selected publications
- Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors. Journal of medicinal chemistry. 2025 Academic Article GET IT
- Discovery of Novel Isofunctional SARS-CoV‑2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening. ACS medicinal chemistry letters. 2025 Academic Article GET IT
- Editor's Note: Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia. 2025 GET IT
-
Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase.
Nature.
2024
Academic Article
GET IT
Times cited: 16 -
Indazole to 2-Cyanoindole Scaffold Progression for Mycobacterial Lipoamide Dehydrogenase Inhibitors Achieves Extended Target Residence Time and Improved Antibacterial Activity.
Angewandte Chemie (International ed. in English).
2024
Academic Article
GET IT
Times cited: 4 -
Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055.
ACS medicinal chemistry letters.
2024
Academic Article
GET IT
Times cited: 4 - Addition to "Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation". 2024 GET IT
-
Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation.
Journal of chemical information and modeling.
2023
Academic Article
GET IT
Times cited: 4 - Corrigendum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential. 2023 GET IT
-
On-demand male contraception via acute inhibition of soluble adenylyl cyclase.
Nature communications.
2023
Academic Article
GET IT
Times cited: 56 -
Structure-Activity Relationship Studies of Antimalarial Plasmodium Proteasome Inhibitors─Part II.
Journal of medicinal chemistry.
2023
Academic Article
GET IT
Times cited: 8 -
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates.
Journal of medicinal chemistry.
2022
Academic Article
GET IT
Times cited: 14 -
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia.
Cancer discovery.
2022
Academic Article
GET IT
Times cited: 45 -
Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential.
Frontiers in physiology.
2022
Academic Article
GET IT
Times cited: 7 -
A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.
ACS medicinal chemistry letters.
2022
Academic Article
GET IT
Times cited: 13 -
Soluble adenylyl cyclase inhibition prevents human sperm functions essential for fertilization.
Molecular human reproduction.
2021
Academic Article
GET IT
Times cited: 44 -
Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10).
ACS medicinal chemistry letters.
2021
Academic Article
GET IT
Times cited: 19 -
Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions.
ACS infectious diseases.
2021
Academic Article
GET IT
Times cited: 4 -
Optimization of lead compounds into on-demand, nonhormonal contraceptives: leveraging a public-private drug discovery institute collaboration†.
Biology of reproduction.
2020
Academic Article
GET IT
Times cited: 16 -
Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells.
Bioorganic & medicinal chemistry letters.
2019
Academic Article
GET IT
Times cited: 44 -
Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors.
Journal of medicinal chemistry.
2019
Academic Article
GET IT
Times cited: 33 -
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Bioorganic & medicinal chemistry letters.
2008
Academic Article
GET IT
Times cited: 137